D 5519
Latest Information Update: 24 Jun 2002
Price :
$50 *
At a glance
- Originator Draco Lakemedel
- Developer Draco Lakemedel; Nonindustrial source
- Class Antiasthmatics; Corticosteroids
- Mechanism of Action Arachidonic acid inhibitors; Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Bronchitis; Inflammatory bowel diseases
Most Recent Events
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 25 Mar 1999 No-Development-Reported for Asthma in Sweden (Inhalation)
- 25 Mar 1999 No-Development-Reported for Bronchitis in Sweden (Inhalation)